Cancer immunotherapy developer Arcus Biosciences will float at the top of its range, scoring exits for Alphabet, Novartis, Celgene and Taiho.
Arcus Biosciences, a US-based immuno-oncology therapy developer backed by several corporates, will raise $120m from its initial public offering when it floats on the New York Stock Exchange later today.
The company, which counts internet and technology conglomerate Alphabet and pharmaceutical firms Novartis, Celgene and Taiho among its investors, priced its stock at $15.00 yesterday, at the top of the IPO’s $13 to $15 range, and will issue 8 million shares, up from 7.1 million.
Founded in 2015, Arcus is…
